Patents Assigned to Cerep
-
Publication number: 20220252611Abstract: Provided are multiplexed methods for characterizing binding of a test compound to different receptor target molecules using mass spectroscopy techniques. The methods employ receptor molecules that have different functions or found in different tissues, such as cerebral cortex, cerebellum, ventricular and hepatic membrane preparations. The methods enable determination of undesirable off-target binding of a test compound. The methods comprise incubation of a heterologous mixture of different receptor target molecules with ligands (known binders), and a test compound. Various wells contain different amounts of molecules for use in construction of concentration curves. Next, unbound ligands are separated from the well contents. Next, ligands that were bound to the receptors are separated. An LC/ESI-MS/MS method may be used to reduce irrelevant mass spectroscopy peaks.Type: ApplicationFiled: March 9, 2022Publication date: August 11, 2022Applicant: EUROFINS CEREPInventors: Manilduth RAMNATH, Benoît FOUCHAQ, Jérôme LAPARRE
-
Publication number: 20090233910Abstract: The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.Type: ApplicationFiled: April 14, 2006Publication date: September 17, 2009Applicant: CEREPInventors: Iuliana Botez, Christelle David-Basei, Nelly Gourlaouen, Eric Nicolai, Fabrice Balavoine, Gerard Valette, Claudine Serradeil-Le Gal
-
Patent number: 7375237Abstract: Pyrrolizine compounds having the formula (I), or pharmaceutically-acceptable salts thereof, are effective in treating inflammatory or immune diseases, where A is a four- to seven-membered saturated ring, K is O or S, and R1, R2, R3 n, and M are defined in the specification.Type: GrantFiled: August 18, 2005Date of Patent: May 20, 2008Assignees: Bristol-Myers Squibb Company, Cerep SAInventors: T. G. Murali Dhar, Dharmpal S. Dodd, Dominique Potin, Michele Launay
-
Patent number: 7238693Abstract: The present invention relates to novel compounds, the preparation and use, particularly therapeutic, thereof. More specifically, it relates to compounds derived from aryl carbamates, the preparation and use thereof, particularly in the field of human and animal health. The compounds according to the invention are preferably 5-HT4 serotoninergic receptor ligands and can therefore be used in the therapeutic or prophylactic treatment of any disorder involving a 5-HT4 receptor. The invention also relates to pharmaceutical compositions comprising such compounds, the preparation and use thereof and treatment methods using said compounds.Type: GrantFiled: February 22, 2002Date of Patent: July 3, 2007Assignees: Cerep, Centre National de la Recherche Scientifique, Institut National de la Santa et de la Recherche Medicale (inserm)Inventors: Eric Nicolai, Sophie Curtet, James Sicsic, Frank Lezoualc'h, Rodolphe Fischmeister, Michel Langlois, Magali Maillet, Michèle Launay
-
Patent number: 7199125Abstract: The present invention is directed to compounds having the formula (I): useful in treating inflammatory and immune diseases, in which K and L are independently, O or S; Q is —C(?O)— or optionally substituted C1-6alkylene; Ar is optionally-substituted aryl or heteroaryl; J1, J2, J3 and Y are selected so that ring A is a five-to-six membered optionally-substituted cycloalkenyl or heterocyclo ring having 0 to 2 nitrogen heteroatoms; R1 is N or C(R9); and R2, and R3, are as defined in the specification.Type: GrantFiled: October 1, 2004Date of Patent: April 3, 2007Assignees: Bristol-Myers Squibb Company, Cerep SAInventors: T. G. Murali Dhar, Edwin Iwanowicz, Michele Launay, Dominique Potin, Magali Jeannine Blandine Maillet, Eric Nicolai
-
Patent number: 7078420Abstract: Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates, enantiomers, and diastereomers, and prodrugs thereof, are useful as inhibitors of LFA-1/ICAM and as anti-inflammatory agents, wherein L and K are O or S; Z is N or CR4b; Ar is an optionally-substituted aryl or heteroaryl; G is a linker attached to T or M or is absent; J, M and T are selected to define a three to six membered saturated or partially unsaturated non-aromatic ring; and R2, R4a, R4b, and R4c are as defined in the specification.Type: GrantFiled: May 24, 2004Date of Patent: July 18, 2006Assignees: Bristol-Myers Squibb Company, Cerep SAInventors: T. G. Murali Dhar, Dominique Potin, Magali Jeannine Blandine Maillet, Michele Launay, Eric Antoine Nicolai, Edwin J. Iwanowicz
-
Patent number: 6977267Abstract: Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates, enantiomers, and diastereomers, and prodrugs thereof, are useful as inhibitors of LFA-1/ICAM and as anti-inflammatory agents, wherein L and K are O or S; Z is N or CR4b; Ar is an optionally-substituted aryl or heteroaryl; G is a linker attached to T or M or is absent; J, M and T are selected to define a three to six membered saturated or partially unsaturated non-aromatic ring; and R2,R4a, R4b, and R4c are as defined in the specification.Type: GrantFiled: October 1, 2002Date of Patent: December 20, 2005Assignees: Bristol-Myers Squibb Company, CEREP SAInventors: T. G. Murali Dhar, Dominique Potin, Magali Jeannine Blandine Maillet, Michele Launay, Eric Antoine Nicolai, Edwin J. Iwanowicz
-
Patent number: 6974815Abstract: The present invention is directed to compounds having the formula (I): useful in treating inflammatory and immune diseases, in which K is O or S; Q is —C(?O)— or optionally substituted C1-4alkylene; Ar is optionally-substituted aryl or heteroaryl; J1, J2, J3, and Y are selected so that ring A is a five-to-six membered optionally-substituted cycloalkenyl or heterocyclo ring having 0 to 2 nitrogen heteroatoms; Z is N or C(R9); and R1, R2, R3 and R9 are as defined in the specification.Type: GrantFiled: October 9, 2003Date of Patent: December 13, 2005Assignees: Bristol-Myers Squibb Company, Cerep SAInventors: T G. Murali Dhar, Dominique Potin, Magali Jeannine Blandine Maillet, Michele Launay, Eric Antoine Nicolai, Edwin J. Iwanowicz
-
Patent number: 6673825Abstract: Urazole compounds having the formula (I), or pharmaceutically-acceptable salts thereof, are effective as anti-inflammatory or immunosuppressive agents, wherein L and K are O or S; Q is a linker such as —O—, —S—, C(═O), and so forth, R1 is an aryl or heteroaryl group, and R3, R4a, R4c, Z, r, s and t are as defined in the specification.Type: GrantFiled: May 21, 2002Date of Patent: January 6, 2004Assignees: Bristol-Myers Squibb Co., Cerep SAInventors: Michele Launay, Dominique Potin, Magali Jeannine Blandine Maillet, Eric Antoine Nicolai, Edwin J. Iwanowicz, T. G. Murali Dhar